astellas
Leading Light for Life

News Release

Astellas Corrects Supplement Documents for Results FY 2013

Tokyo, Japan, June 12, 2014 – Astellas Pharma Inc. (Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) announced that it corrects its Supplement Documents for result FY 2013.

1. Details of Corrections

In the sections of "Addition to Property, Plant and Equipment/ Depreciation and Amortisation", some figures related to Addition to Property, Plant and Equipment had errors and have been corrected as follows;

Page 3 (J-GAAP)
(Error)
FY 2013 Full Year Results 27.4 billion yen Change -4.6 billion yen Change(%) -14.5%

(Correction)
FY 2013 Full Year Results 25.7 billion yen Change -6.4 billion yen Change(%) -19.8%

Page 13 (IFRS)
(Error)
FY 2013 Full Year Results 27.3 billion yen Change -4.8 billion yen Change(%) -14.9%
FY 2014 Full Year Forecasts Change(%) 20.9%

(Correction)
FY 2013 Full Year Results 25.7 billion yen Change -6.4 billion yen Change(%) -19.9%
FY 2014 Full Year Forecasts Change(%) 28.4%

#######

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com/en